达格列净联合常规抗心衰药物治疗慢性心力衰竭患者的临床效果观察  

Observation on clinical effect of dapagliflozin combined with conventional anti-heart failure drugs in the treatment of patients with chronic heart failure

作　　者：范志岗 吴明明[1] 张巍[1] FAN Zhi-gang;WU Ming-ming;ZHANG Wei(Department of Cardiovascular Medicine,Rudong County People's Hospital,Nantong 226400,China)

机构地区：[1]如东县人民医院心血管内科,226400

出　　处：《中国实用医药》2024年第19期95-98,共4页China Practical Medicine

摘　　要：目的 探讨达格列净片联合常规抗心力衰竭(心衰)药物(呋塞米、螺内酯、美托洛尔缓释片、沙库巴曲缬沙坦钠)在慢性心力衰竭患者中的临床疗效。方法 84例慢性心力衰竭患者为研究对象,采用简单化随机法分为对照组和观察组,每组42例。对照组患者采用常规抗心力衰竭药物呋塞米、螺内酯、美托洛尔缓释片、沙库巴曲缬沙坦钠进行治疗,观察组在对照组基础上联用达格列净片进行治疗。比较两组患者的临床疗效、心功能指标[左室射血分数(LVEF)和左室舒张末期内径(LVEDD)]、炎性指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]及不良反应发生率。结果 与对照组(81.0%)比较,观察组患者临床总有效率(97.6%)明显更高(P<0.05)。治疗后,观察组患者LVEF(49.62±4.81)%明显高于对照组的(40.53±4.55)%, LVEDD(52.19±2.09)mm明显低于对照组的(63.68±2.33)mm,差异均具有统计学意义(P<0.05)。治疗后,观察组患者血清IL-6、TNF-α水平分别为(33.32±4.31)、(12.27±2.09)ng/L,明显低于对照组的(56.92±5.38)、(35.85±4.63)ng/L(P<0.05)。与对照组(7.1%)比较,观察组患者的不良反应发生率(4.8%)无明显差异(P>0.05)。结论 慢性心力衰竭患者经常规抗心力衰竭药物与达格列净片联合治疗临床疗效显著,心功能指标和机体内炎性反应得到有效改善,且联合用药安全性良好,值得临床推广。Objective To explore the clinical efficacy of dapagliflozin combined with conventional anti-heart failure drugs(furosemide,spironolactone,metoprolol sustained-release tablets,sacubitril valsartan sodium)in the treatment of patients with chronic heart failure.Methods 84 patients with chronic heart failure were studied and divided into a control group and an observation group by simple random method,with 42 cases in each group.The control group was treated with conventional anti-heart failure drugs(furosemide,spironolactone,metoprolol sustained-release tablets,sacubitril valsartan sodium),while the observation group was treated with dapagliflozin tablets on the basis of the control group.Both groups were compared in terms of clinical efficacy,cardiac function indicators[left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDD)],inflammatory indicators[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]and incidence of adverse reactions.Results Compared with the control group(81.0%),the total clinical effective rate of the observation group(97.6%)was significantly higher(P<0.05).After treatment,the observation group had significantly higher LVEF of(49.62±4.81)%than(40.53±4.55)%in the control group,and significantly lower LVEDD of(52.19±2.09)mm than(63.68±2.33)mm in the control group.The differences were statistically significant(P<0.05).After treatment,the serum levels of IL-6 and TNF-αwere(33.32±4.31)and(12.27±2.09)ng/L in the observation group,which were significantly lower than(56.92±5.38)and(35.85±4.63)ng/L in the control group(P<0.05).Compared with the control group(7.1%),the incidence of adverse reactions in the observation group(4.8%)had no significant difference(P>0.05).Conclusion In chronic heart failure patients,the combination of conventional anti-heart failure drugs and dapagliflozin tablets has significant clinical efficacy,and the cardiac function indicators and inflammatory response in the body has been effectively improved,and the safety of joint use of dru

关 键 词：慢性心力衰竭 达格列净 沙库巴曲缬沙坦钠 临床效果 

分 类 号：R541.6[医药卫生—心血管疾病]